Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?

Authors: Signorelli D, Macerelli M, Proto C, Vitali M, Cona MS, Agustoni F, Zilembo N, Platania M, Trama A, Gallucci R, Ganzinelli M, Pelosi G, Pastorino U, de Braud F, Garassino MC, Russo GL Abstract Malignant pleural mesothelioma is a rare cancer with a cause-effect relationship to asbestos exposure. The prognosis is poor and chemotherapy seems the best treatment option. In the last two decades a deeper understanding of mesothelioma carcinogenesis and invasiveness mechanisms has prompted research efforts to test new agents in patients with malignant pleural mesothelioma, but the results have been modest. Attractive preclinical data disappointed in subsequent experimental phases. Other promising agents failed to improve patient outcomes due to high toxicity. Interesting suggestion...

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

from MedWorm: Mesothelioma http://ift.tt/1RXsaFt